

6. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *N Eng J Med* 2001;344:2195-207.
7. Peters MJ, Symmons DPM, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. *Ann Rheum Dis* 2010;69:325-31.
8. Radford EP, Doll R, Smith PG. Mortality among patients with ankylosing spondylitis not given X-ray therapy. *N Eng J Med* 1977;297:572-6.
9. Heeneman S, Daimen MJAP. Cardiovascular risks in spondyloarthropathies. *Curr Opin Rheumatol* 2007;19:358-62.
10. Zochling J, Braun J. Mortality in ankylosing spondylitis. *Clin Exp Rheumatol* 2008;26(suppl. 51):S80-S84.
11. Feltelius N, Ekblom A, Elmquist P. Cancer incidence among patients with ankylosing spondylitis in Sweden. *Ann Rheum Dis* 2003;62:1185-8.
12. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. *Ann Rheum Dis* 1993;52:174-6.
13. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA et al. Cardiovascular risk profile of patients with ankylosing spondylitis and psoriatic arthritis. *Semin Arthritis Rheum* 2004;34:585-92.
14. Han C, Robinson DW jr, Hackett MV et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. *J Rheumatol* 2006;33:2167-72.
15. Peters MJ, Visman I, Nielsen MM et al. Ankylosing spondylitis: a risk factor for myocardial infarction? *Ann Rheum Dis* 2010;69:579-81.
16. O'Neill TW, King G, Graham IM. The heart in ankylosing spondylitis. *Ann Rheum Dis* 1992;51:705-6.
17. Youssef W, Russell AS. Cardiac, ocular, and renal manifestations of seronegative spondyloarthropathies. *Curr Opin Rheumatol* 1990;2:582-5.
18. Dik VK, Peters MJ, Dijkmans PA et al. The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis. *Scand J Rheumatol* 2010;39:38-41.
19. Divecha H, Sattar N, Rumley A et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. *Clin Sci (Lond)* 2005;109:171-6.
20. Castelli WP, Garrison RJ, Wilson PW et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. *JAMA* 1986;256:2835-8.
21. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. *Ann Rheum Dis* 2009;68:460-9.
22. Sari I, Okan T, Akar S et al. Impaired endothelial function in patients with ankylosing spondylitis. *Rheumatology* 2006;45:283-6.
23. Malesci D, Niglio A, Mennillo GA et al. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. *Clin Rheumatol* 2007;26:710-4.
24. Van Halm VP, van Denderen JC, Peters MJ. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. *Ann Rheum Dis* 2006;65:1473-7.
25. Papadakis JA, Sidiropoulos PJ, Karvounaris SA et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. *Clin Exp Rheumatol* 2009;27:292-8.
26. Peters MJ, van Eijk IC, Smulders YM et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. *Rheumatol* 2010;37:161-6.
27. Dunn AL. The effectiveness of lifestyle physical activity interventions to reduce cardiovascular disease. *Am J Lifestyle Med* 2009;3:115-185.
28. Ford ES. Does exercise reduce inflammation? *Epidemiology* 2002;13:561-8.
29. Bolten WW. Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. *Ann Rheum Dis* 2006;65:7-13.
30. Westlake SL, Colebatch AN, Baird J et al. The effect of methotrexate on cardiovascular risk in patients with rheumatoid arthritis: a systemic literature review. *Rheumatology (Oxford)* 2010;49:295-307.
31. Da Silva JA, Jacobs JW, Kirwan JR et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. *Ann Rheum Dis* 2006;65:285-93.
32. Davis JM 3rd, Kremers HM, Crowson CS et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population based study. *Arthritis Rheum* 2007;56:820-30.
33. Jacobsson LT, Turesson C, Gulfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. *J Rheumatol* 2005;32:1213-8.
34. Mathieu S, Dubost J-J, Tournadre A et al. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. *Joint Bone Spine* 2010;77:50-2.
35. van Eijk IC, de Vries MK, Levels JHM et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade. *Arthritis Rheum* 2009;60:1324-30.
36. van Eijk IC, Peters MJ, Serné EH et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. *Ann Rheum Dis* 2009;68:362-6.
37. Karkucak M, Capkin E, Alver A et al. The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis. *Clin Rheumatol* 2010;29:303-7.
38. Spanakis E, Sidiropoulos P, Papadakis J et al. Modest but sustained increase in serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. *J Rheumatol* 2006;33:2440-6.
39. Pollono EN, Lopez-Olivo MA, Lopez JA et al. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. *Clin Rheumatol* 2010;29:947-55.
40. Leyon JJ, Jaiveer S, Connolly DL et al. Statin prescription is essential in peripheral vascular disease. *J Vasc Interv Radiol* 2010;21:175-7.



## LÆGEMIDDELSTYRELSEN

### TILSKUD TIL LÆGEMIDLER

Lægemedelstyrelsen meddeler, at der pr. 16. maj 2011 ydes generelt tilskud efter sundhedslovens § 144 til følgende lægemidler:

- (S-01-EC-03) Arzolahid øjendråber\*, Actavis A/S  
 (L-02-BB-03) Bictamid tabletter\*, Arrow Pharma Aps  
 (C-03-CA-02) Burinex tabletter\*, EuroPharmaDK ApS  
 (N-06-AB-10) Escitalopram »Actavis« tabletter\*, Actavis A/S  
 (L-02-AE-02) Procren Depot pulver og solvens til injektion\*, Abacus Medicine Aps  
 (R-03-AX-06) Seretide inhalationsspray\*, 2care4 ApS  
 (N-03-AX-21) Trobalt tabletter, GlaxoSmithKline Pharma A/S

gruppe uden klausulering over for bestemte sygdomme.

- (C-08-CA-05) Adalat LA depottabletter\*, 2care4 ApS

lægemedlet er klausuleret til personer, der opfylder følgende sygdomsklausul: Patienter med behandlingskrævende hypertension eller anden form for hjerte-kar-sygdom, hvor behandling med dihydropridin-calciumantagonister med generelt tilskud uden klausulering ikke tolereres, eller i helt særlige tilfælde – efter lægens samlede kliniske vurdering af patientens tilstand – ikke er hensigtsmæssig. En betingelse for at opnå tilskud er, at lægen har skrevet »tilskud« på recepten.

- (C-10-AX-09) Ezetrol tabletter\*, EuroPharmaDK ApS

lægemedlet er klausuleret til pensionister eller til personer, der opfylder følgende sygdomsklausul: Patienter med behandlingskrævende hyperlipidæmi, hvor behandling med generelt tilskudsberettiget statin har vist sig utilstrækkelig, eller som ikke tåler disse lægemidler. En betingelse for at opnå tilskud er, at lægen har skrevet »tilskud« på recepten.

Denne bestemmelse trådte i kraft den 16. maj 2011.